Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis

Published:2016-05-23 Issue:5 Volume:174 Page:730-747
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Park Sophie¹,Fenaux Pierre²,Greenberg Peter³,Mehta Bhakti⁴,Callaghan Fiona⁵,Kim Christopher⁴,Tomita Dianne⁴,Xu Hairong⁴

Affiliation:

1. CHU de Grenoble Clinique Universitaire d'Hématologie Université Grenoble Alpes Grenoble France

2. Hôpital St Louis/Université Paris 7 Paris France

3. Stanford University Medical Center Stanford CA USA

4. Amgen Inc. Thousand Oaks CA USA

5. Amgen Inc. South San Francisco CA USA

Funder

Amgen

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.14116

Reference34 articles.

1. Fatigue in cancer patients compared with fatigue in the general United States population

2. Report of an international working group to standardize response criteria for myelodysplastic syndromes;Cheson B.D.;Blood,2000

3. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

4. Incidence and Burden of the Myelodysplastic Syndromes

5. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MDS patient registries - achievements and challenges;Annals of Hematology;2024-08-23

2. Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes;Therapeutic Advances in Hematology;2024-01

3. Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists;Clinics in Laboratory Medicine;2023-12

4. Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival;Leukemia & Lymphoma;2023-05-31

5. Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data;Turkish Journal of Hematology;2023-05-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3